Literature DB >> 1355924

Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

B M Cohen1, T Tsuneizumi, R J Baldessarini, A Campbell, S M Babb.   

Abstract

After a single dose of the butyrophenone neuroleptic haloperidol, behavioral effects and detectable drug levels in rat brain can last for several weeks. To determine if such persistence is a general property of neuroleptics, we compared drug levels and effects after IP administration of two butyrophenones (haloperidol and bromperidol), a high potency (fluphenazine) and a low potency (chlorpromazine) phenothiazine. Drug levels in brain tissue were measured by high pressure liquid chromatography and behavioral effects monitored as inhibition of apomorphine-induced stereotypy. Estimated near terminal elimination half-lives (t 1/2) from brain for acutely administered chlorpromazine (20 mg/kg) and fluphenazine (1 mg/kg) were 0.41 and 0.62 days, respectively, and neither drug was detectable after 4 days. Fluphenazine given daily for 5 days showed an only slightly slower elimination (t 1/2 = 1.1 days). In contrast, near-terminal elimination half-lives from brain for haloperidol and bromperidol (both at 1 mg/kg, IP) were much longer (6.6 and 5.8 days, respectively), and each was detectable for 21 days after dosing. Inhibition of apomorphine-induced stereotypy correlated highly (r = 0.95) with brain levels of haloperidol. For fluphenazine, given once or repeatedly, early inhibition was replaced within 1 week by supersensitivity to apomorphine which persisted for up to 3 weeks. These findings, indicating marked differences in clearance and recovery times after dosing with butyrophenones and phenothiazines, have clear implications for studies of the effects of neuroleptic drugs in rats.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355924     DOI: 10.1007/bf02245121

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

1.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

2.  Persistence of haloperidol in the brain.

Authors:  B M Cohen; S Babb; A Campbell; R J Baldessarini
Journal:  Arch Gen Psychiatry       Date:  1988-09

3.  Behavioral effects of a single neuroleptic treatment grow with the passage of time.

Authors:  S M Antelman; D Kocan; D J Edwards; S Knopf; J M Perel; R Stiller
Journal:  Brain Res       Date:  1986-10-15       Impact factor: 3.252

4.  Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.

Authors:  L Ereshefsky; M W Jann; S R Saklad; C M Davis
Journal:  J Clin Psychiatry       Date:  1986-09       Impact factor: 4.384

5.  Prolonged pharmacologic activity of neuroleptic drugs.

Authors:  J W Hubbard; D Ganes; K K Midha
Journal:  Arch Gen Psychiatry       Date:  1987-01

6.  N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.

Authors:  S X Xu; Y Hatada; L E Black; I Creese; D R Sibley
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

7.  Plasma HVA in psychiatric patients: longitudinal studies.

Authors:  J I Javaid; R P Sharma; P G Janicak; J M Davis
Journal:  Psychopharmacol Bull       Date:  1990

8.  Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.

Authors:  D Kirch; S Hattox; J Bell; R Murphy; R Freedman
Journal:  Psychiatry Res       Date:  1983-07       Impact factor: 3.222

9.  Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection.

Authors:  E R Korpi; B H Phelps; H Granger; W H Chang; M Linnoila; J L Meek; R J Wyatt
Journal:  Clin Chem       Date:  1983-04       Impact factor: 8.327

10.  Prolonged antidopaminergic actions of single doses of butyrophenones in the rat.

Authors:  A Campbell; R J Baldessarini; M H Teicher; N S Kula
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  9 in total

1.  Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Hiroyoshi Takeuchi; Kensuke Nomura; Akira Tanabe; Koichiro Watanabe; Gohei Yagi; Haruo Kashima
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

2.  Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.

Authors:  Johannes Kornhuber; Jens Wiltfang; Peter Riederer; Stefan Bleich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat.

Authors:  Matthew L MacDonald; Molly E Eaton; Joshua T Dudman; Christine Konradi
Journal:  Biol Psychiatry       Date:  2005-05-01       Impact factor: 13.382

4.  Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.

Authors:  A M Bester; B H Harvey
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

Review 5.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Effect of chronic lithium treatment with or without haloperidol on number and sizes of neurons in rat neocortex.

Authors:  R W Licht; J O Larsen; D Smith; H Braendgaard
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

7.  Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine.

Authors:  A Campbell; R J Baldessarini; J L Neumeyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.

Authors:  A V Terry; D A Gearhart; S Warner; E J Hohnadel; M-L Middlemore; G Zhang; M G Bartlett; S P Mahadik
Journal:  Neuroscience       Date:  2007-09-14       Impact factor: 3.590

9.  Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity.

Authors:  Thomas A Munro; Loren M Berry; Ashlee Van't Veer; Cécile Béguin; F Ivy Carroll; Zhiyang Zhao; William A Carlezon; Bruce M Cohen
Journal:  BMC Pharmacol       Date:  2012-05-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.